Clinical Trial Update: Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating stellate ganglion block with lidocaine for treating COVID-19-induced parosmia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parosmia

Drugs mentioned

• Lidocaine (Lidocaine)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Parosmia | Phase 3 | Status: RECRUITING